Myeloproliferative neoplasms (MPNs) are rare cancers and include diseases of the blood and bone marrow. MPNs involve dysregulation at the multipotent hematopoietic stem cell (CD34). MPNs occur when the bone marrow produces too many red blood cells, platelets, or certain white blood cells. The primary subtypes include myelofibrosis, polycythemia vera, and essential thrombocythemia.

Sangeetha Venugopal, MDMyelofibrosis | September 20, 2023
Myelofibrosis Awareness Day is marked on September 20th each year.
View More
Leah LawrenceMeeting News | September 19, 2023
Researchers presented updated data from the phase I XPORT-MF-034 trial at the Eleventh SOHO Annual Meeting.
Leah LawrenceMyelofibrosis | September 19, 2023
The open-label ACE-536-MF-001 study included patient cohorts grouped by transfusion dependance and ruxolitinib therapy.
Leah LawrenceMyelofibrosis | September 18, 2023
In PERSIST-2, treatment with pacritinib demonstrated a significant SVR benefit compared with the best available therapy, incl
Leah SherwoodMyelofibrosis | September 16, 2023
Nearly all myelofibrosis patients are estimated to develop anemia over the course of the disease.
Cailin ConnerMeeting News | September 10, 2023
The need for phlebotomies substantially decreased in those who received ruxolitinib after hydroxyurea.
Cailin ConnerMeeting News | September 10, 2023
The combined average cost for the index hospitalization and two-year TE-related readmissions was $30,285.
Cecilia BrownMeeting News | September 9, 2023
Patients with MPNs faced higher direct and indirect costs and were significantly more likely to take disability leave.
Cailin ConnerPolycythemia Vera | September 9, 2023
The investigators sought to investigate the diagnostic landscape of polycythemia vera in LMICs.
Cecilia BrownMyeloproliferative Neoplasms | September 9, 2023
Researchers presented data from the randomized withdrawal phase of the study at the SOHO Annual Meeting.
Cecilia BrownMyelofibrosis | August 21, 2023
Ruxolitinib, an oral JAK1/JAK2 inhibitor, initially received FDA approval in 2011.
Cecilia BrownMyelofibrosis | August 21, 2023
Researchers conducted the study because the mechanism by which pacritinib improves anemia has not been elucidated.
Cecilia BrownMyelofibrosis | August 18, 2023
Researchers conducted an indirect comparison analysis of multiple clinical trials to address the question.
Leah SherwoodMyelofibrosis | August 9, 2023
In June 2023, the manufacturer of the drug initiated XPORT-MF-034, a pivotal phase III clinical trial.
Leah SherwoodAcute Myeloid Leukemia | July 17, 2023
From Houston, Texas, to Beirut, Lebanon, the SOHO global community continues to grow thanks to its Ambassador Program.
Cecilia BrownMyelofibrosis | July 14, 2023
At a median follow-up of 55 weeks, 90% of patients completed 24 weeks of treatment and 56% completed 48 weeks of treatment.
Cecilia BrownMyelofibrosis | July 13, 2023
Initiation of ruxolitinib therapy within two years of diagnosis was associated with increased response rates in all patients.
Leah SherwoodPolycythemia Vera | July 6, 2023
Dr. Harrison discusses survey results from the LANDMARK survey in patients with polycythemia vera and their physicians.
Cecilia BrownMyeloproliferative Neoplasms | June 20, 2023
Just under half (43%) of patients receiving ruxolitinib achieved a CR, while 26% achieved a CR on the best available therapy.
Cecilia BrownPolycythemia Vera | June 19, 2023
The trial included patients with PV who had at least three therapeutic phlebotomies in the 28 weeks prior to enrollment.
Cecilia BrownMyeloproliferative Neoplasms | June 16, 2023
However, achieving a spleen volume reduction on the best available therapy was not linked with improved survival.
Cecilia BrownMeeting News | June 15, 2023
Dr. Mascarenhas and colleagues identified 11,371 patients with myelofibrosis, finding that 76.8% had concurrent anemia.
Cecilia BrownMyeloproliferative Neoplasms | June 15, 2023
The median JAK2 mutant allele burden at baseline significantly differed among MPN subsets.
Cecilia BrownMeeting News | June 14, 2023
Dr. Kuykendall and colleagues presented their findings during the 2023 European Hematology Association Congress.
Blood Cancer TalksMyeloproliferative Neoplasms | June 13, 2023
Dr. Sekeres also speaks about his time on the FDA ODAC and his latest book, titled "Drugs and the FDA."
Leah SherwoodVideo Insights | June 13, 2023
Dr. Krecak presented the research during the 2023 EHA Congress.
Keightley AmenMyelofibrosis | June 11, 2023
Spleen volume reduction predicts OS in patients with myelofibrosis who are taking pacritinib.
Keightley AmenMyelofibrosis | June 8, 2023
A new study is exploring add-on treatment of CK0804 in patients with myelofibrosis and suboptimal response to ruxolitinib.
Keightley AmenMyeloproliferative Neoplasms | June 8, 2023
The phase II MANIFEST study suggested that pelabresib could be beneficial in myelofibrosis.
Cecilia BrownMyeloproliferative Neoplasms | June 8, 2023
The study indirectly compared safety outcomes from phase II and phase III trials of momelotinib and fedratinib.
Cecilia BrownMeeting News | June 7, 2023
The median time to achieving the first spleen volume reduction of at least 35% from baseline was 12 weeks.
Prithviraj Bose, MDMyelofibrosis | June 7, 2023
Prithviraj Bose, MD, and colleagues presented results of the study during the 2023 ASCO Annual Meeting.
Keightley AmenMyelofibrosis | June 7, 2023
The authors concluded that treatment with INCB057643 monotherapy was generally well tolerated.
Keightley AmenMeeting News | June 7, 2023
The case-control study used information from the Veterans Affairs Informatics and Computing Infrastructure database.
Cecilia BrownMeeting News | June 7, 2023
The study is designed to evaluate the efficacy, safety, and tolerability of ropeginterferon alfa-2b-njft in adults with ET.
Cecilia BrownLatest Issue | June 7, 2023
Luspatercept-aamt demonstrated “favorable outcomes” compared with epoetin alfa across common mutations in MDS.
Keightley AmenMyelofibrosis | June 6, 2023
Researchers followed the patients for three years after their final dose of luspatercept.
Keightley AmenMyelofibrosis | June 5, 2023
Jakatinib may be a new effective treatment option for patients with myelofibrosis.
Cecilia BrownMyelofibrosis | June 5, 2023
Pacritinib demonstrates consistent efficacy for spleen and symptom response in patients with MF regardless of blood counts.
Keightley AmenMyelofibrosis | June 5, 2023
Selinexor plus ruxolitinib was effective in certain subgroups of patients with myelofibrosis.
Keightley AmenMyeloproliferative Neoplasms | June 3, 2023
In patients with Afib, MPNs are linked to an increased risk of hospital readmissions for bleeding and arterial thrombosis.
Cecilia BrownMyelofibrosis | June 3, 2023
The pooled analysis set included patients from both arms of the intent-to-treat populations in SIMPLIFY-1 and SIMPLIFY-2.
Cecilia BrownMyelofibrosis | June 1, 2023
The trial will enroll certain patients who had an "inadequate response” to ruxolitinib alone.
Leah SherwoodMyeloproliferative Neoplasms | May 22, 2023
The main aim of treatment is preventing thrombotic complications.
Blood Cancer TalksBlood Cancer Talks | May 19, 2023
Dr. Tefferi discusses risk stratification systems for primary myelofibrosis, transplant considerations, and more.
Cecilia BrownMyelofibrosis | May 15, 2023
They detected mutated TP53 in 49 (13%) patients, with 30 of those patients showing a multihit configuration.
Cecilia BrownMyelofibrosis | May 11, 2023
The model was developed and validated using data from the CIBMTR and EBMT registries.
Cecilia BrownMyelofibrosis | May 10, 2023
The study evaluated longitudinal symptom score changes to “complement the interpretation of the landmark symptom ...
Cecilia BrownMeeting News | April 19, 2023
Planning for a phase III trial of the combination is underway.
Leah SherwoodMeeting News | April 19, 2023
Jan Bewersdorf, MD, discusses a current ongoing phase I study investigating the combination of ruxolitinib and abemaciclib.
Latest News

September 22, 2023